New genomic research amends earlier triple negative breast cancer finding

15 abril 2015

Investigators tried to validate a previously reported molecular finding on triple negative breast cancer that many hoped would lead to targeted treatments for the aggressive disease. Instead, they discovered that the findings were limited to a single patient and could not be applied to further clinical work. This discovery amends the earlier work and underscores the importance of independent study validation and careful assay development.